EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta‐Analysis

Elham Ashrafi iD, Lauren Young, Lucy C Fox iD, Stephen B Ting iD, Erica M Wood iD, Zoe K McQuilten iD

eJHaem · 2026-04 · 7 (2)

DOI: 10.1002/jha2.70226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift eJHaem, online erschienen am 27.02.2026. Verfasst von Elham Ashrafi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit School of Public Health and Preventive Medicine Monash University Melbourne Australia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunosuppressive therapy (IST) is standard first‐line treatment for severe aplastic anaemia (AA) in patients ineligible for allogeneic transplantation. Thrombopoietin receptor agonists (TPO‐RAs) are increasingly added to IST to improve haematologic recovery, but long‐term safety remains uncertain.

Methods

We conducted a PRISMA‐guided systematic review and meta‐analysis. MEDLINE, EMBASE and CENTRAL were searched from inception to April 2025. Randomised controlled trials and observational studies comparing TPO‐RA plus IST with IST alone were analysed separately using random‐effects models. The primary outcome was overall haematologic response at 6 months; secondary outcomes included response at 3 and 12 months, complete response, survival, relapse and clonal evolution.

Results

Twenty studies (2 randomised and 18 observational) were included. In randomised trials, TPO‐RA plus IST showed a non‐significant trend towards higher overall response at 6 months (OR 2.01; 95% CI 0.76–5.28), while complete response was significantly higher at 3 and 6 months. Observational studies consistently demonstrated higher overall and complete response rates. No significant differences were observed in survival, relapse or clonal evolution.

Conclusion

Limited randomised evidence does not demonstrate statistically significant benefit across all outcomes, while observational data suggest potential haematologic advantages. Further high‐quality trials are required to clarify the effectiveness and long‐term safety of adding a TPO‐RA to IST in AA. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission

Schlagwörter

Stichwörter der Autor:innen

aplastic anaemiahaematologic responseimmunosuppressive therapymeta‐analysisthrombopoietin receptor agonists

Autor:innen und Institutionen

  • Transfusion Research Unit School of Public Health and Preventive Medicine Monash University Melbourne Australia.
  • Department of Haematology Eastern Health and Monash University Melbourne Australia.

ORCID-Profile: Elham Ashrafi, Lucy C Fox, Stephen B Ting, Erica M Wood, Zoe K McQuilten

Zitieren

APA

Ashrafi, E., Young, L., Fox, L. C., Ting, S. B., Wood, E. M., & McQuilten, Z. K. (2026). Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta‐Analysis. eJHaem, 7(2). https://doi.org/10.1002/jha2.70226

Vancouver

Ashrafi E, Young L, Fox LC, Ting SB, Wood EM, McQuilten ZK. Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta‐Analysis. eJHaem. 2026;7(2). doi:10.1002/jha2.70226

BibTeX
@article{Ashrafi2026,
  author = {Ashrafi, Elham and Young, Lauren and Fox, Lucy C and Ting, Stephen B and Wood, Erica M and McQuilten, Zoe K},
  title = {Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta‐Analysis},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/jha2.70226}
}
Kostenlos starten →